Results. In the post implementation period, 868 patients were prescribed targeted antibiotics. Fifty-one percent (442) prescriptions required adjustment for drug selection, route, dose, or duration. Loading dose was indicated but not prescribed in 31% (266) of prescriptions, 14% (118) had inappropriate maintenance dose and 13% (110) were continued beyond standard recommended durations. Compliance was noted with 50% of ASP recommendations. Departments with high compliance rates included Neurosurgery (63%), Urology (62%), and Medicine (59%). Significant decreases in cost ( Figure 1) were noted for ertapenem (Rs 106200 reduced to Rs 15930), colistin (Rs 1368258 to Rs 338322) and linezolid (Rs 919296 to Rs 137472) (all P < 0.05) (1USD~64 Rs). Utilization of Colistin and Linezolid decreased from 422 vials to 94 (22%) and 1320 vials to 202 (15%), respectively.
Grading the Impact of a Standardized Β Lactam Antibiotic Allergy
Background. Approximately 30% of patients at our institution have β-lactam (BL) antibiotic allergies documented in their medical record. This translates to high use of non-β-lactams (NBL) or other structurally dissimilar agents. Patients treated with NBL are three times as likely to experience an adverse effect or be readmitted for infection. BL allergy assessment, re-challenge and de-labeling remain an important target for antimicrobial stewardship (AST). Published protocols have been validated at large teaching institutions with improvements in documentation and the care of patients with labeled allergies, including drug challenge protocols and desensitization for true allergies. At BIDMC, a multidisciplinary committee developed a guidance document to include a series of standard questions, medical record review and appropriate clarifications for the medical record. The guideline also includes recommendations an algorithm for the approach to drug challenge or desensitization.
Methods. The guideline was launched in September 2016 and this study examined the first 4 months of use. The primary endpoint compared the number of full desensitizations requiring ICU admission, and number of graded/full challenges preand post-implementation. Aztreonam, which is structurally dissimilar to other BL, was used as a surrogate marker of avoidance of BL.
Results. Pre-implementation rates of graded challenges and full desensitizations were equivalent. This was bifurcated by 1,000% within 4 months such that the use of graded challenge was 10 times the desensitization rate (Figure 1) . Aztreonam use decreased from a 2.33 patient days of therapy (pDOT) per 1,000 days in September to 1.74 in January (Figure 2 ). The decrease in utilization was most pronounced on the General Medicine units. Utilization was driven most heavily by patients being treated by the Hematology Oncology Service. No adverse reactions were documented during any post guideline β lactam challenges.
Conclusion. Introduction of a multidisciplinary guideline by AST and Allergy led to preferred utilization of graded challenge over full ICU desensitization and an overall decrease in aztreonam use. 
Use of a Clostridium difficile

